StoxPiramal Pharma vs Wockhardt: share price & financials comparison
NSE: PPLPHARMA vs WOCKPHARMA · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Piramal Pharma vs Wockhardt at a glance
Piramal Pharma (PPLPHARMA) has a market capitalisation of ₹31,791 Cr, against ₹31,541 Cr for Wockhardt (WOCKPHARMA). Over the past year Wockhardt has returned +49.0%, compared with +17.2% for Piramal Pharma. Wockhardt earns a higher return on equity (7.9% vs -2.6%). Piramal Pharma comes out ahead on valuation, growth and technicals. Wockhardt comes out ahead on size, profitability and financial health. Across the scored metrics below, Piramal Pharma leads on 6 and Wockhardt on 7. On StoxGud's 10-point checklist, Piramal Pharma scores 6/10 and Wockhardt scores 7/10.
| Metric | Piramal Pharma | Wockhardt |
|---|---|---|
| Size | ||
| Market cap | ₹31,791 Cr | ₹31,541 Cr |
| Revenue (latest FY) | ₹8,869 Cr | ₹3,373 Cr |
| Net profit (latest FY) | ₹-326 Cr | ₹213 Cr |
| Valuation | ||
| P/E | — | 76.9 |
| P/B | 3.90 | 6.12 |
| Dividend yield | 0.06% | — |
| Profitability | ||
| Return on equity | -2.6% | 7.9% |
| Net profit margin | -2.1% | 10.9% |
| Operating margin | 12.3% | 20.4% |
| Growth | ||
| Revenue growth (YoY) | +28.1% | +23.9% |
| Net profit growth (YoY) | — | +1.3% |
| Revenue CAGR (multi-year) | +7.8% | +4.5% |
| Financial health | ||
| Debt to equity | 0.70 | 0.42 |
| Momentum | ||
| 1-month return | +17.9% | -9.5% |
| 1-year return | +17.2% | +49.0% |
| 3-year CAGR | +30.2% | +102.7% |
| 5-year CAGR | — | +35.5% |
| 10-year CAGR | — | +10.0% |
| Distance from 52W high | -0.3% | -16.4% |
| Technicals | ||
| RSI (14) | 76 | 49 |
| Price vs 200-day avg | +33.9% | +13.4% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Piramal Pharma | Wockhardt |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 6/10 | 7/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Piramal Pharma or Wockhardt?
Piramal Pharma has a market cap of ₹31,791 Cr and Wockhardt has a market cap of ₹31,541 Cr as of 06 Nov 2026.
Which gave better returns in the last year, Piramal Pharma or Wockhardt?
Wockhardt did better: Piramal Pharma returned +17.2% and Wockhardt returned +49.0% over one year.
Is Piramal Pharma or Wockhardt a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Piramal Pharma scores 6/10 and Wockhardt scores 7/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.